ATP Life Science Ventures, L.P. → Stoke Therapeutics, Inc. STOK

Stake: — Shares: —

Composite Decision Signal · PASS (LOW BASE-RATE EDGE) Conviction Score: 25/100

Passive Schedule 13G filer baseline
Held by 1 tracked 13F institutional manager
Elevated short days-to-cover (10.2 DTC)

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

1 transaction

1 buys · 0 sales · 0 awards/exercises

Issuer Cluster

2 13D/G filings on this issuer

1 other filing besides this one

Filer Track Record

3 filings by this filer

2 other filings in the data moat

Short Interest · settle 2026-09-30

DTC 10.17

11,505,410 shares short · +3.2% vs prior

Institutional Consensus · 2025-12-31

Held by elite portfolio managers

1 holder · $38.79M

Point72 Asset Mgmt

Form 4 Insider Transactions · last 365d

Date	Insider	Role	Type	Shares	Price	Value
2026-04-03	Kahn Clare	director	Award	30,782	$32.79	$1.01M

Other 13D/G Filings on Stoke Therapeutics, Inc.

Filed	Form	Filer	Stake	Shares
2020-11-27	SC	Apple Tree Partners IV, L.P.	—	—	view →

Other Filings by ATP Life Science Ventures, L.P.

Filed	Form	Issuer	Stake	Shares
2021-06-29	SC	Akero Therapeutics, Inc.	—	—	view →
2020-11-27	SC	Stoke Therapeutics, Inc. STOK	—	—	view →

Want this depth on every filing the moment it hits SEC EDGAR?

Free $0 (48h-delayed alerts) · Individual $49/mo (real-time) · Team & API $199/mo · Enterprise.

See pricing →